BiomX (PHGE) Return on Capital Employed (2019 - 2026)
BiomX (PHGE) posted Return on Capital Employed of 1691.11% for Q1 2026, down 291.37% sequentially from 432.1% in Q4 2025, and down 156954.0% YoY from N/an in Q1 2025.
BiomX (PHGE) Return on Capital Employed (2019 - 2026) Analysis & Trends
BiomX has reported Return on Capital Employed for 8 years, with the latest figure at 1691.11% in Q1 2026.
- Quarterly Return on Capital Employed fell 156954.0% year-over-year to 1691.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1691.11% (down 156954.0% YoY) and the FY2025 annual result came in at 228.73%, down 5658.0% from the prior year.
- Return on Capital Employed eased to 1691.11% in Q1 2026 per PHGE's latest filing, from 432.1% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 54.64% in Q1 2022 and troughed at 1691.11% in Q1 2026.
- A 5-year average of 212.54% and a median of 90.73% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed jumped 4355 bps in 2024, then slumped 156954 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 66.75% in 2022, then plunged by 113 bps to 141.87% in 2023, then jumped by 30 bps to 99.24% in 2024, then tumbled by 335 bps to 432.1% in 2025, then sank by 291 bps to 1691.11% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 1691.11%, 432.1%, and 150.32% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | BiomX | 361,408.40 | -806,591.60 | - | -1,691.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,691.11% |
| Dec 31, 2025 | -432.10% |
| Sep 30, 2025 | -150.32% |
| Jun 30, 2025 | -121.39% |
| Mar 31, 2025 | -121.57% |
| Dec 31, 2024 | -99.24% |
| Sep 30, 2024 | -61.64% |
| Jun 30, 2024 | -68.77% |
| Dec 31, 2023 | -141.87% |
| Sep 30, 2023 | -105.19% |
| Jun 30, 2023 | -82.22% |
| Mar 31, 2023 | -77.07% |
| Dec 31, 2022 | -66.75% |
| Sep 30, 2022 | -65.97% |
| Jun 30, 2022 | -60.85% |
| Mar 31, 2022 | -54.64% |
| Dec 31, 2021 | -51.51% |
| Sep 30, 2021 | -55.39% |
| Jun 30, 2021 | -59.62% |
| Mar 31, 2021 | -53.90% |